A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease

PLoS ONE

Volumn 12, Issue 10, 2017, Pages

  Pillai, Nadia ^a   Dusheiko, Mark ^a,b,c   Burnand, Bernard ^a   Pittet, Valérie ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; INFLIXIMAB; MESALAZINE; VEDOLIZUMAB;

CLINICAL OUTCOME; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MARKETING; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; QUALITY OF LIFE; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASES;

COST-BENEFIT ANALYSIS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 85030456231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0185500     Document Type: Review

References (91)

1. Hanauer SB. Inflammatory Bowel Disease. New England Journal of Medicine. 1996; 334(13):841–8. https://doi.org/10.1056/NEJM199603283341307 PMID: 8596552
2. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010; 4(1):28–62. https://doi.org/10.1016/j.crohns.2009.12.002 PMID: 21122489.
3. Bodger K. Cost Effectiveness of Treatments for Inflammatory Bowel Disease. Pharmacoeconomics. 2011; 29(5):387–401. https://doi.org/10.2165/11584820-000000000-00000 PMID: 21271748
4. Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(11):493. https://doi.org/10.1038/ncpgasthep0318 PMID: 16355136.
5. Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn’s disease. The Lancet. 2017; 389 (10080):1741–55. https://doi.org/10.1016/s0140-6736(16)31711-1
6. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. The Lancet. 2017; 389(10080):1756–70. https://doi.org/10.1016/s0140-6736(16)32126-2
7. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015; 12(9):537–45. https://doi.org/10.1038/nrgastro.2015.135 PMID: 26284562.
8. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic Advances in Gastroenterology. 2015; 8(2):66–82. https://doi.org/10.1177/1756283X14558193 PMID: 25729432
9. Stone CD. The economic burden of inflammatory bowel disease: Clear problem, unclear solution. Digestive Diseases and Sciences. 2012; 57(12):3042–4. https://doi.org/10.1007/s10620-012-2417-8 PMID: 23086111
10. Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis. 2013; 7:322–37. https://doi.org/10.1016/j.crohns.2013.01.010 PMID: 23395397
11. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1):46–54 e42; quiz e30. https://doi.org/10.1053/j.gastro.2011.10.001 PMID: 22001864.
12. M’Koma AE. Inflammatory bowel disease: An expanding global health problem. Clinical Medicine Insights: Gastroenterology. 2013; 6:33–47. https://doi.org/10.4137/CGast.S12731 PMID: 24833941
13. Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoeconomics & Outcomes Research. 2014; 6:431–43. PMID: 25336980; PubMed Central PMCID: PMCPMC4199854.
14. Stone CD. The economic burden of inflammatory bowel disease: clear problem, unclear solution. Dig Dis Sci. 2012; 57(12):3042–4. https://doi.org/10.1007/s10620-012-2417-8 PMID: 23086111.
15. Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes: Fourth Edition. New York: Oxford University Press; 2015.
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org.
17. OECD. Inflation (CPI) (indicator) 2017 [cited 2017 01 February 2017].
18. OECD. Purchasing power parities (PPP) (indicator) 2017 [cited 2017 01 February 2017)].
19. NICE. NICE Guide to the methods of technology appraisal. In: Excellence NIfHaC, editor. 2013.
20. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What Is the Price of Life and Why Doesn’t It Increase at the Rate of Inflation? Arch Intern Med. 2003; 163(14):1637–41. https://doi.org/10.1001/archinte.163.14.1637 PMID: 12885677
21. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93(2):118–24. https://doi.org/10.2471/BLT.14.138206 PMID: 25883405; PubMed Central PMCID: PMCPMC4339959.
22. Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ. 2015; 24(1):1–7. https://doi.org/10.1002/hec.3130 PMID: 25488707.
23. Goldman D, Lakdawalla D, Philipson T. The economic value of medical innovation. Washington, DC: Milken Institute, 2012.
24. Drummond MJT. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996; 313:275–83. PMID: 8704542
25. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment. 2004; 8(36). PMID: 15361314
26. University of York Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York, 2009.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Medicine. 2009; 6(7):1–6. 10.1371/.
28. Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis. 2012; 18(9):1608–16. https://doi.org/10.1002/ibd.21904 PMID: 21905173; PubMed Central PMCID: PMCNIHMS350629 PMC3381977.
29. Park KT, Tsai R, Perez F, Cipriano LE, Bass D, Garber AM. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Annals of surgery. 2012; 256(1):117–24. https://doi.org/10.1097/SLA.0b013e3182445321 PMID: 22270693.
30. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn’s disease: A lifetime cost-utility analysis. PharmacoEconomics. 1997; 11(5):444–53. PMID: 10168032.
31. Panes J, Guilera M, Ginard D, Hinojosa J, Gonzalez-Carro P, Gonzalez-Lara V, et al. Treatment cost of ulcerative colitis. Is apheresis with Adacolumn cost-effective? Digestive and Liver Disease. 2007; 39 (7):617–25. https://doi.org/10.1016/j.dld.2007.03.007 PMID: 17531555.
32. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: A cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics. 2007; 26(11–12):1509–20. https://doi.org/10.1111/j.1365-2036.2007.03548.x PMID: 17931345.
33. Bakhshai J, Bleu-Laine R, Jung M, Lim J, Reyes C, Sun L, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. Journal of Medical Economics. 2010; 13(1):63–9. https://doi.org/10.3111/13696990903543424 PMID: 20028199.
34. Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterology. 2016; 3(1):e000093. https://doi.org/10.1136/bmjgast-2016-000093 PMID: 27195130; PubMed Central PMCID: PMCPMC4860720.
35. Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001; 120(7):1640–56. PMID: 11375946.
36. Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, et al. Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. 66 p.
37. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, et al. Systemic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technology Assessment. 2003; 7(3). PMID: 12709295.
38. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn’s disease: A lifetime cost-utility analysis. International Journal of Technology Assessment in Health Care. 2004; 20(3):274–9. PMID: 15446756.
39. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006; 24(8):767–81. PMID: 16898847.
40. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease—Modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology and Therapeutics. 2008; 28(1):76–87. https://doi.org/10.1111/j.1365-2036.2008.03709.x PMID: 18410558.
41. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Alimentary Pharmacology and Therapeutics. 2009; 30(3):265–74. https://doi.org/10.1111/j.1365-2036.2009.04033.x PMID: 19438428.
42. Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease. European Journal of Gastroenterology and Hepatology. 2009; 21(11):1302–9. https://doi.org/10.1097/MEG.0b013e32832a8d71 PMID: 19465858.
43. Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009; 27(7):609–21. https://doi.org/10.2165/11312710-000000000-00000 PMID: 19663531.
44. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technology Assessment (Winchester, England). 2011; 15(6):1–244. https://doi.org/10.3310/hta15060 PMID: 21291629.
45. Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrence in crohn’s disease: Results of a decision analysis. American Journal of Gastroenterology. 2011; 106(11):2009–17. https://doi.org/10.1038/ajg.2011.237 PMID: 21788991.
46. Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis. Digestive Diseases and Sciences. 2012:1–9. https://doi.org/10.1007/s10620-011-2021-3 PMID: 51615099.
47. Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease. Journal of Crohn’s and Colitis. 2012; 6(1):77–85. https://doi.org/10.1016/j.crohns.2011.07.007 PMID: 22261531.
48. Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe crohn’s disease. Pharmacotherapy. 2012; 32(6):515–26. https://doi.org/10.1002/j.1875-9114.2011.01053.x PMID: 22528603.
49. Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease. European Journal of Health Economics. 2013; 14(6):853–61. https://doi.org/10.1007/s10198-012-0430-7 PMID: 22975794.
50. Saito S, Shimizu U, Nan Z, Mandai N, Yokoyama J, Terajima K, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysis. Journal of Crohn’s & colitis. 2013; 7(2):167–74. https://doi.org/10.1016/j.crohns.2012.04.007 PMID: 22626508.
51. Erim D, Mahendraratnam N, Okafor P, Wheeler S. The value of vedolizumab as rescue therapy in moderate-severe Crohn’s disease patients with adalimumab non-response in the USA. Journal of Crohns Colitis. 2015; 9(8):669–75.
52. Taleban S, Van Oijen MGH, Vasiliauskas EA, Fleshner PR, Shen B, Ippoliti AF, et al. Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn’s Colitis. Digestive Diseases and Sciences. 2016; 61(2):550–9. https://doi.org/10.1007/s10620-015-3886-3 PMID: 26434930.
53. Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Lobo A. Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2016; 34(12):1241–53. https://doi.org/10.1007/s40273-016-0436-6 PMID: 27480631.
54. Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2008; 28(11–12):1287–96. https://doi.org/10.1111/j.1365-2036.2008.03856.x PMID: 18808444.
55. Tsai HH, Black C. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Expert Review of Pharmacoeconomics and Outcomes Research. 2016:1–5. PMID: 612920480.
56. Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. American Journal of Gastroenterology. 2008; 103(12):3094–105. https://doi.org/10.1111/j.1572-0241.2008.02130.x PMID: 18775007.
57. Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SPL. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. Journal of Crohn’s and Colitis. 2009; 3(1):32–7. https://doi.org/10.1016/j.crohns.2008.10.004 PMID: 21172245.
58. Connolly MP, Nielsen SK, Currie CJ, Marteau P, Probert CS, Travis SP. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. Journal of Crohn’s and Colitis. 2009; 3(3):168–74. https://doi.org/10.1016/j.crohns.2009.02.005 PMID: 21172266.
59. Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness & Resource Allocation. 2009; 7:20. https://doi.org/10.1186/1478-7547-7-20 PMID: 20003364; PubMed Central PMCID: PMCPMC2797497.
60. Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics. 2010; 13(1):148–61. https://doi.org/10.3111/13696990903562861 PMID: 20141380.
61. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. European Journal of Health Economics. 2010; 11(1):67–76. https://doi.org/10.1007/s10198-009-0199-5 PMID: 19844750.
62. Prenzler A, Yen L, Mittendorf T, von der Schulenburg JM. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Services Research. 2011; 11:157. https://doi.org/10.1186/1472-6963-11-157 PMID: 21729262; PubMed Central PMCID: PMCPMC3146407.
63. Connolly MP, Boersma C, Oldenburg B. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands. Netherlands Journal of Medicine. 2012; 70(6):272–7. PMID: 22859419.
64. Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clinical Gastroenterology and Hepatology. 2012; 10(10):1143–51. https://doi.org/10.1016/j.cgh.2012.05.003 PMID: 22610010.
65. Chaudhary MA, Fan T. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands. Biologics in Therapy. 2013; 3(1):45–60. PMID: 22013027452.
66. Connolly MP, Kuyvenhoven JP, Postma MJ, Nielsen SK. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing. Journal of Crohn’s and Colitis. 2014; 8(5):357–62. https://doi.org/10.1016/j.crohns.2013.09.015 PMID: 24094599.
67. Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis: A single technology appraisal. In: NICE, editor. 2014.
68. Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess. 2016; 20(39):1–326. https://doi.org/10.3310/hta20390 PMID: 27220829; PubMed Central PMCID: PMCPMC4904186.
69. Beilman CL, Thanh NX, Ung V, Ma C, Wong K, Kroeker KI, et al. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology & Hepatology. 2016; 2016:5315798. https://doi.org/10.1155/2016/5315798 PMID: 27781203.
70. Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/ Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PLoS ONE [Electronic Resource]. 2016; 11(8):e0160444. https://doi.org/10.1371/journal.pone.0160444 PMID: 27494322; PubMed Central PMCID: PMCPMC4975491.
71. Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European Journal of Clinical Pharmacology. 2016; 72(11):1319–25. https://doi.org/10.1007/s00228-016-2103-4 PMID: 27497991.
72. Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016; 36(5):472–81. https://doi.org/10.1002/phar.1742 PMID: 27007213.
73. Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, et al. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics. 2016; 34 (10):1023–38. https://doi.org/10.1007/s40273-016-0409-9 PMID: 27125898.
74. Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017. https://doi.org/10.1007/s10198-017-0879-5 PMID: 28271250.
75. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health. 2005; 8(5):521–33. https://doi.org/10.1111/j.1524-4733.2005.00045.x PMID: 16176491
76. Moss A. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015; 3(1):63–8. https://doi.org/10.1093/gastro/gou087 PMID: 25567472; PubMed Central PMCID: PMCPMC4324872.
77. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011; 106(4):674–84. https://doi.org/10.1038/ajg.2011.60 PMID: 21407178.
78. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146(2):392–400 e3. https://doi.org/10.1053/j.gastro.2013.10.052 PMID: 24512909.
79. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease. The new england journal o f medicine. 2010; 362:1383–95.
80. Panaccione R, Gosh S. Optimal use of biologics in the management of Crohn’s disease. Therapeutic Advances in Gastroenterology. 2010; 3(3):179–89. 10.1177/. https://doi.org/10.1177/1756283X09357579 PMID: 21180600
81. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet. 2017; 389 (10086):2304–16. https://doi.org/10.1016/s0140-6736(17)30068-5
82. Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017; 14(1):22–31. https://doi.org/10.1038/nrgastro.2016.155 PMID: 27729659.
83. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015; 12 (12):720–7. https://doi.org/10.1038/nrgastro.2015.150 PMID: 26323879.
84. Gregor J, McDonald J, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in Crohn’s disease. Inflammatory Bowel Disease. 1997; 3(4):265–76.
85. Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010; 4(3):275–82. https://doi.org/10.1016/j.crohns.2009.11.010 PMID: 21122516.
86. Woehl A, Hawthorne AB, Morgan CL, Punekar Y, McEwan P. Pg113 the Epidemiology and Health Care Resource Use in Patients with Crohn’s Disease: A Population Based Uk Study. Value in Health. 2007; 10(6):A355. https://doi.org/10.1016/s1098-3015(10)65262-x
87. Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: Transferable or Not? Pharmacoeconomics. 2009; 27(9):767–79. https://doi.org/10.2165/11314120-000000000-00000 PMID: 19757870
88. Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 2015; 10 (12) (no pagination)(e0145087). PMID: 608001011.
89. Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A systematic review of economic studies on biological agents used to treat Crohn’s disease. Inflammatory Bowel Diseases. 2013; 19(12):2673–94. https://doi.org/10.1097/MIB.0b013e3182916046 PMID: 23792552.
90. Schneider Y, Saumoy M, Cohen-Mekelburg S, Steinlauf AF, Scherl EJ. The cost-effectiveness of vedolizumab for inflammatory bowel disease: A review of the current literature. Gastroenterology and Hepatology. 2016; 12(10):617–21. PMID: 27917076.
91. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010; 19 (3):350–64. https://doi.org/10.1002/hec.1486 PMID: 19378354.